Drug intelligence / Profile preview

KiOnutrime-Cs

Development stage: Unknown
Lead developer: Kitozyme
Administration: Oral

Overview

KiOnutrime-Cs is a **proprietary, non-animal, vegan chitosan** ingredient developed for weight management and metabolic health applications. It is obtained from the cell wall of non-genetically modified *Aspergillus niger* mycelium (fungal source), not from crustaceans as in traditional chitosan products. Its main mechanism involves **binding dietary fats and bile acids in the digestive tract**, thus reducing fat absorption and supporting weight loss and the management of cholesterol levels. Clinical studies show its use can promote a statistically significant weight reduction when taken before meals, with established safety and tolerability.

Brand names: KiOnutrime-Cs
Other names: fungal chitosanAspergillus niger chitosannon-animal chitosan

Beyond the preview

Go deeper on KiOnutrime-Cs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KiOnutrime-Cs.

Explore the full profile